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ABSTRACT
Introduction: The mental and physical health of
individuals with a psychotic illness are typically poor.
When adhered to, medication can reduce relapse.
However, despite adherence, relapse remains common
and functional outcomes often remain compromised.
Compliance is also typically low. Cardiovascular-related
morbidity and mortality is also elevated, along with
several important modifiable health risk behaviours.
Access to psychosocial interventions is therefore
important, but currently limited. Telephone delivered
interventions represent a promising solution, although
further clarity is needed. Accordingly, we aim to
provide an overview and critical analysis of the current
state of evidence for telephone delivered psychosocial
interventions targeting key health priorities in adults
with a psychotic disorder, including (1) relapse, (2)
adherence to psychiatric medication and/or (3)
modifiable cardiovascular health risk behaviours.
Methods and analysis: Our methods are informed by
published guidelines. The review is registered and any
protocol amendments will be tracked. Ten electronic
peer-reviewed and four grey literature databases have
been identified. Preliminary searches have been
conducted for literature on psychosocial telephone
interventions targeting relapse, medication adherence
and/or health risk behaviours in adults with a psychotic
disorder. Articles classified as ‘evaluation’ will be
assessed against standardised criteria and checked by an
independent assessor. The searches will be re-run just
before final analyses and further studies retrieved for
inclusion. A narrative synthesis will be reported,
structured around intervention type and content,
population characteristics and outcomes. Where possible,
‘summary of findings’ tables will be generated for each
comparison. For the primary outcome of each trial, when
data are available, we will calculate a risk ratio and its
95% CI (dichotomous outcomes) and/or effect size
according to Cohen’s formula (continuous outcomes).
Ethics and dissemination: No ethical issues are
foreseen. Findings will be disseminated widely to
clinicians and researchers via journal publication and
conference presentation(s).
Trial registration number: PROSPERO
CRD42015025402.
INTRODUCTION
Psychotic illnesses (eg, schizophrenia spec-
trum and bipolar disorder) are chronic,
relapsing conditions characterised by distor-
tions in thinking, perception and emotional
response.1 These symptoms can have a pro-
found impact on quality of life and function-
ing.2 Psychotic illnesses are also associated
with a mortality rate double that of the
general population3 4 and a shortening of
life expectancy by up to 19 years.5
Cardiovascular disease (CVD) is the single
largest cause of death among this group,
accounting for more premature deaths than
suicide.6–8 Rates of major health risk beha-
viours associated with CVD (smoking,
physical inactivity, alcohol use and low fruit
and vegetable intake) are all higher in
people living with psychotic illnesses.9–12
Furthermore, second generation antipsycho-
tics (SGA), which are commonly used in the
treatment of psychotic illnesses, are also asso-
ciated with a range of serious metabolic side
effects, including changes in body weight,
glucose utilisation and lipid status.13
The well-being of individuals with psych-
otic illnesses is further compromised by poor
access to treatment. Although SGAs can
reduce relapse,14 rates of non-compliance
are as high as 50%.15 A large scale study has
also found that almost three-quarters of
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participants diagnosed with schizophrenia chose to dis-
continue their medication within 18 months.16
Furthermore, for those individuals who are compliant
and do beneﬁt from medication, they often continue to
experience difﬁculties within important psychosocial
domains (eg, employment, social function) and con-
tinue to relapse.2 14 This points to the importance of
psychosocial interventions as an adjunct to traditional
medication management.
Cognitive-behavioural therapy (CBT) is one of the
most researched psychosocial interventions in psychosis.
CBT is associated with small to moderate positive effects
for a range of psychotic symptomatology and accom-
panying difﬁculties17 18 and also demonstrates promise
as an option for improving adherence to antipsychotic
medication.19 Furthermore, increasing evidence sup-
ports the role of CBT alone, or in combination with,
other psychosocial approaches (eg, motivational inter-
viewing) for modifying health risk behaviours among
individuals with psychosis.20–22 However, despite psycho-
social interventions like CBT being recommended by
Australian,23 UK24 25 and other international clinical
guidelines26 27 for the treatment of schizophrenia and
other psychotic disorders, of those likely to beneﬁt, only
10% or less have access.28–30 Barriers to access include
availability of trained clinicians, accessibility of support
services, embarrassment and perceived stigma associated
with seeking help.28–30 Given the limitations of medica-
tion management, improving access to psychosocial
interventions represents an important priority for
enhancing the well-being of individuals living with a
psychotic illness.
Why it is important to do this review
Technology-based interventions represent a promising
avenue for improving access to healthcare. Indeed, a
recent systematic reviews points to the acceptability and
feasibility of telephone delivered interventions (alone,
or in combination with other remote access technology)
within schizophrenia.31 However, this review was
restricted to schizophrenia and did not focus on psycho-
social interventions or summarising the evidence for key
health priorities. Given that the problems seen in schizo-
phrenia surrounding relapse, SGA compliance, CVD
and treatment access are also shared by other psychotic
disorders, in this systematic review we aim to provide an
overview and critical analysis of the current state of evi-
dence for psychosocial telephone delivered interven-
tions targeting key health priorities in adults with a
psychotic disorder, including (1) relapse, (2) adherence
to psychiatric medication and/or (3) modiﬁable cardio-
vascular health risk behaviours.
Objectives
The following three questions will be addressed. For
adults with a psychotic disorder:
1. Do telephone delivered psychosocial interventions
targeting (1) relapse, (2) adherence to psychiatric
medication and/or (3) modiﬁable cardiovascular
health risk behaviours result in changes to:
A. Indicators of relapse, including psychiatric symp-
tomatology (positive and negative symptoms,
depression, anxiety), the number and duration
of hospitalisations, functioning and quality of life
B. Medication adherence, including dose count
(doses taken); dose days (days where correct
number of doses taken); dose time (doses
taken on schedule)
C. Health behaviours (eg, smoking, substance use,
physical activity, fruit and vegetable
consumption)
D. Severity of cardiovascular disease (CVD) risk,
including CVD risk index; quantity, severity of
CVD risk factors (eg, weight, body mass index
(BMI), waist circumference, blood pressure,
plasma lipids, insulin and glucose)
2. Is the effect of telephone delivered psychosocial
interventions targeting (1) relapse, (2) adherence to
psychiatric medication and/or (3) modiﬁable cardio-
vascular health risk behaviours on the above listed
treatment outcomes inﬂuenced by:
A. other intervention components (eg, individual
and/or group face-to-face components;
supplementary materials; other technology)
B. implementation factors (staff training; interven-
tion ﬁdelity, treatment engagement/adherence)
C. process measures/mediators/mechanisms (eg,
cognitive (empowerment/self-efﬁcacy/motiv-
ation); behavioural (eg, active coping, including
managing urges); relational (eg, therapeutic
alliance))
3. What is the evidence for the feasibility of telephone
delivered psychosocial interventions for relapse pre-
vention, adherence to psychiatric medication and/or
health risk behaviours, including commentary on
economic outcomes and service user and/or pro-
vider satisfaction.
METHODS AND ANALYSIS
This systematic review will be informed by published guide-
lines32 and reported according to the Preferred Reporting
Items for Systematic Review and Meta-analysis (PRISMA).33
Eligibility criteria
Eligibility of papers for inclusion in the review will be
informed by inclusion and exclusion criteria applied to
each of the following domains: types of studies, types of
participants, types of interventions and comparison con-
ditions, and the outcome measures assessed. Inclusion
and any exclusion criteria within each of these domains
is described in turn below:
Types of studies
In accordance with the objective of providing an over-
view of the current evidence for telephone delivered
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interventions in adults with a psychotic disorder, liberal
design criteria will be adopted. The following designs
will be included—randomised controlled trials (cluster
and parallel design); cross-over trial; case series or case–
controls; one-arm trial; non-randomised trials; cross-
sectional or cohort studies and case reports. As broad
inclusion criteria may increase risk of bias, this will be
assessed using the Collaboration’s Risk of Bias tool, as
described in the Cochrane Handbook for Systematic
Review of Interventions (32 detailed under risk of bias
assessment below). Qualitative only designs will not be
included.
Types of participants
Studies that include adults (>18) with a psychotic dis-
order, as deﬁned by any criteria will be included.
Diagnosis of study participants may be self-reported or
conﬁrmed via clinical interview. Study participants may
be residing in the community, rehabilitation, treatment
and/or correctional facility. We will include studies with
populations involving adults with non-psychotic disor-
ders only if more than 50% had a psychotic disorder, or
if data limited to those with psychotic disorders are
available.
In order to better inform research and clinical care,
we intend to describe the clinical state (acute vs posta-
cute vs partial remission vs remission), stage (eg, ﬁrst
episode vs early illness vs persistent) and whether the
studies target particular clinical presentations (eg, nega-
tive symptoms, positive symptoms, treatment-resistant
illnesses).
Types of interventions
The intervention of interest is telephone support target-
ing (1) relapse prevention, (2) adherence to psychiatric
medication and/or (3) modiﬁable health risk
behaviours.
‘Relapse prevention’ will be deﬁned as telephone
support designed to recognise and act on early warning
signs of episode recurrence and/or enhance coping
strategies (including medication compliance), the
number and duration of hospitalisations and/or the
impact of the illness on functioning and/or quality of
life.
‘Adherence to psychiatric medication’ will be deﬁned
as telephone support intended to affect adherence with
prescribed, self-administered medication for mental dis-
orders. Ethical standards for adherence research dictate
that attempts to increase adherence must be judged by
their clinical beneﬁts, not simply their effects on adher-
ence rates.34 Accordingly, adherence studies will only be
included if both adherence and treatment effects are
measured.
‘Modiﬁable health risk behaviours’ will be deﬁned as
telephone support that targets health behaviours (nutri-
tion, physical activity, smoking and substance use) asso-
ciated with modiﬁable cardiovascular risk factors
(weight, cholesterol, blood glucose and blood pressure).
To be included, the telephone support must:
1. Be administered over the telephone using person
delivered (professional or layperson) spoken word
(ie, text, web-based and/or automated systems col-
lecting or transmitting data will not be included)
2. Utilise one or more psychological strategies to modify
relapse risk, adherence to psychiatric medication
and/or health risk behaviours. Psychological strat-
egies will be deﬁned as supportive counselling, psy-
choeducation (including brief advice), cognitive
behavioural (including problem solving, dialectical
behavioural therapy, acceptance and commitment
therapy), mindfulness and/or motivational
interviewing
3. Comprise at least one telephone session, of at least
10 min, delivered by a healthcare professional and/
or non-professional/layperson/peer/consumer who
has been trained in delivering the intervention
The telephone support may be a standalone interven-
tion and/or delivered in combination with other treat-
ment components, including pharmacological. However,
studies with multiple components will only be included
if the telephone is the predominant method of interven-
tion delivery. This is deﬁned as studies in which at least
50% of the total number of participant contacts are con-
ducted by telephone. Interventions delivered in any
setting (eg, community, hospital, rehabilitation or resi-
dential treatment centre, etc) will be included.
Types of comparison conditions
The telephone support may be compared to inactive
(eg, standard care, waiting list control) and/or active
controls (eg, pharmacological and/or psychological)
whereby telephone is not the predominant method of
intervention delivery (eg, individual, group or internet).
Types of outcome measures
1. Indicators of relapse, including psychiatric symptom-
atology (positive and negative symptoms, depression,
anxiety), the number and duration of hospitalisa-
tions, functioning and quality of life
2. Medication adherence, including dose count (doses
taken); dose days (days where correct number of
doses taken); dose time (doses taken on schedule)
3. Health behaviours (eg, smoking, substance use, phys-
ical activity, fruit and vegetable consumption)
4. Severity of cardiovascular risk, including CVD risk
index; quantity, severity of CVD risk factors (eg,
weight, BMI, waist circumference, blood pressure,
plasma lipids, insulin, glucose)
5. Treatment engagement (eg, quantity/frequency/dur-
ation of telephone support attendance)
6. Process measures/mediators/mechanisms (eg, cogni-
tive (empowerment/self-efﬁcacy/motivation); behav-
ioural (eg, active coping, including managing urges);
process (eg, therapeutic alliance))
7. Feasibility, including economic outcomes (eg, cost,
resource use, cost-effectiveness) and/or satisfaction/
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preference. Qualitative outcomes regarding partici-
pant and/or relative satisfaction will be reported as
described.
Outcomes may be clinician and/or patient rated;
assessed by objective and/or subjective indices (eg,
blood, urine, actigraph, questionnaire, monitoring
form/diary) with or without collateral information (eg,
using a family member to validate use) and of any time
frame (eg, baseline, short and/or medium and/or long-
term follow-up).
Information sources
Search strategy
Consistent with methods detailed in Cochrane
Guidelines for systematic reviews,32 the search strategy
will be conducted as follows. First, in May 2015 we identi-
ﬁed 10 relevant scientiﬁc electronic databases
(MEDLINE, PubMed, EMBASE, CINAHL, Science
Direct, Wiley, PsychInfo, Central, Amed, Scopus) and
four electronic non-scientiﬁc databases (Translating
Research into Practice; Virginia Commonwealth
University; Project Cork; Prevention, Information and
Evidence Library) to search. Search terms related to
telephone will be combined with psychosis-related
search terms and then outcome-related search terms
(see online supplementary appendix 1 for the full
MEDLINE search strategy).
Abstract, title, key words and subject headings speciﬁc
to each of the identiﬁed database will be searched. All
subject headings will be exploded so that narrower
terms are included. No limits will be placed on publica-
tion year. Publications must be available in English.
Reference lists of identiﬁed publications will be manu-
ally searched to identify any additional publications. All
publications will be organised in reference manager
Endnote. The searches will be re-run just before ﬁnal
analyses and further studies retrieved for inclusion.
Classification of studies
The titles and abstracts of identiﬁed references will be
classiﬁed in a three-step process.
Step 1: identification of studies for exclusion
AKB will review the titles and/or abstracts and exclude
articles if they: (1) are duplicates, (2) do not focus on
adults with a psychotic disorder, (3) do not focus on
telephone delivered support, or (4) if the outcomes,
process and/or predictor variables do not include or
speciﬁcally relate to relapse, medication adherence
and/or health behaviours, (5) are not journal articles,
reports, book chapters or newsletter articles. If eligibility
is unclear from the title and/or abstract, the full text
article will be accessed and assessed.
Step 2: classification of studies
The abstracts and/or full text of the remaining studies
will be examined by AKB to identify studies that are: (1)
Evaluation, deﬁned as an evaluation of a telephone
delivered intervention as per the PICO criteria outlined
above; (2) Reviews, including summaries, descriptive, crit-
ical and/or systematic reviews; Discussion, deﬁned as
general discussion of telephone delivered interventions,
including development, principles, methods and imple-
mentation. References that are not evaluation, review or
discussion papers (eg, treatment manuals) will classiﬁed
as ‘Other’.
Step 3: cross checking
Publications from step two will be reclassiﬁed by AB, for
cross-checking. In case of disagreement, the ﬁnal classiﬁ-
cation will be made by consensus, with the involvement
of GH, PK, KB and/or SB. The articles excluded in step
one will not be cross-checked because they will not be
relevant to the review. The evaluation studies identiﬁed
in step two will retained for further examination.
Data extraction from evaluation studies
Data extraction will be performed by AB and checked
by AT. Extraction forms will be piloted on several papers
and modiﬁed as needed before use. When multiple
reports of the same study are identiﬁed (eg, related
journal articles, conference proceedings which are then
published), data from each report will be extracted sep-
arately and then combined across multiple data collec-
tion forms. Methodological critique and assessment of
risk of bias will be performed independently by AB and
AT. In the event of disagreement, ﬁnal ratings will be
made via consensus, following discussion with GH, PJK,
KB and/or SB. In the event that inadequate trial details
are reported, study authors will be contacted no more
than twice to obtain further information.
To enable methodological critique of both observa-
tional research and RCTs, criteria for data extraction will
be adapted from the Downs and Black Scale35 and the
Cochrane Handbook for Systematic Reviews32 and
include
1. Participant information, including n-values at each
stage of the study (and reasons for non-
participation), treatment setting, eligibility criteria,
descriptive data including age, gender, ethnicity,
socioeconomic status, diagnostic criteria and treat-
ment history
2. Methods, including study design, country, setting(s),
methodological limitations reported, methodological
limitations observed (eg, recruitment allocation and
data collection methods; blinding; comparability of
groups at baseline; appropriateness of analysis
methods)
3. Interventions, including number of groups, duration
of treatment (number, frequency and duration of
phone and non-phone components), delivery
method(s), description of control intervention(s)
4. Primary and secondary outcomes, including data col-
lection sources/methods, percentage of treatment
sessions attended, other process measures/
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mediators/mechanisms, economic outcomes,
satisfaction-related qualitative outcomes, follow-up
period
5. Results, including indicators of relapse, medication
adherence, health behaviours, severity of cardiovascu-
lar risk, treatment engagement, process measures/
mediators/mechanisms, economic outcomes and
patient satisfaction collected at all available follow-up
time points.
Methodological critique of evaluation research
To provide a thorough overview of the literature we will
implement procedures to evaluate the quality of both
observational studies and RCTs. A narrative synthesis of
the ﬁndings from the included studies will be reported,
structured around intervention type and content, popu-
lation characteristics, and outcomes. This qualitative
review will be supplemented with the following quantita-
tive measures.
For observational studies, methodological quality will
be assessed against the Downs and Black Scale.35
Criteria will be assigned a yes (1 point); no (0 points);
or unclear (0 points) rating. All criteria will have the
same weight, and a quality score ranging from 0 to 27
points will be calculated for each study.
For RCTs, methodological quality will be assessed
against the 11-item Physiotherapy Evidence Database
(PEDro) scale.36 Consistent with published reviews of
psychological interventions 21 37 two items regarding
blinding of participants and therapists will not be scored
in the present review, as these criteria are not appropri-
ate for the studies under review. The remaining nine cri-
teria will be assigned a assigned a yes (1 point) or no (0
points) rating, and a quality score ranging from 0 to 8
points will be calculated for each study (as item one is
not included in the quality score36;).
Risk of bias will also be assessed using the
Collaboration’s Risk of Bias tool, as described in the
Cochrane Handbook for Systematic Review of Interventions.32
We will judge each item as being high, low or unclear
risk, as per the criteria provided by Higgins and Green32
and provide a quote from the study report and a justiﬁ-
cation for our judgement for each item in the risk of
bias table. Given that growing empirical evidence sug-
gests that sequence generation and allocation conceal-
ment are particularly important potential sources of
bias, studies will be deemed to be at the highest risk of
bias if either item is scored as ‘high’ or ‘unclear’.
Measures of treatment effect
Where possible, ‘summary of ﬁndings’ (SOF) tables will
be generated for each comparison (phone vs multicom-
ponent phone; phone vs other active control; phone vs
other inactive control). SOF tables will provide key infor-
mation regarding evidence quality, the magnitude of
effect of the interventions examined, and a summary of
available data on the outcome variables deﬁned under
‘Outcome Measures’ above.
Scale-derived data
We intend to include continuous data from rating scales
only if:
A. The psychometric properties of the instrument have
been described in a peer-review journal
B. The instrument was not written or modiﬁed by one
of the authors for that particular trial
C. The instrument was self-report or completed by an
independent assessor (in the event that this is not
clearly reported, a note will be made in ‘Description
of Studies’)
Data presented in graphs and figures
Where possible, we intend to extract data that is only
represented in graphs and ﬁgures, but only if the same
result(s) are independently derived by AB and AT.
Dichotomous outcome measures
When data are available, a risk ratio (RR) and its 95%
CI will be provided for the primary outcome of each
trial. RR has been selected in preference to ORs as evi-
dence suggests that RR is more intuitive38 and clinicians
tend to misinterpret ORs as RR.39
Continuous outcome measures
When data are available, effect sizes will be calculated
according to Cohen’s formula, to allow for comparison
across studies. Effect sizes will be interpreted according
to published guidelines, where 0.2–0.49 is deﬁned as a
small effect size, 0.5–0.79 is moderate and greater than
0.8 is large.
A study will be considered to have a positive outcome if
at least 50% of reported outcomes demonstrate a
between-group difference in favour of the telephone
support group at the end of the intervention. Positive
maintenance outcome(s) will be evidenced when this
effect is also evident at short and/or medium and/or
long-term follow-up (deﬁned as 1–6; 7–12 and
>12 months after intervention completion, respectively).
We anticipate there will be limited scope for meta-analysis
due to the range of different outcome measures.
ETHICS AND DISSEMINATION
As no primary data collection will be undertaken, no
formal ethical assessment is required.
We plan to present the ﬁndings of this systematic
review for peer-review in an appropriate journal. We also
intend to present to clinicians and researchers at appro-
priate conferences.
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